DNA methylation of blood cells is associated with prevalent type 2 diabetes in a meta-analysis of four European cohorts.
ATP Binding Cassette Transporter, Subfamily G, Member 1
Adult
Aged
Blood Cells
/ metabolism
Carnitine O-Palmitoyltransferase
Carrier Proteins
Case-Control Studies
CpG Islands
Cross-Sectional Studies
DNA Methylation
Diabetes Mellitus, Type 2
/ blood
Epigenesis, Genetic
Epigenome
/ genetics
European Union
/ statistics & numerical data
Female
Genome-Wide Association Study
/ methods
Histone Deacetylases
Humans
Male
MicroRNAs
Middle Aged
Prevalence
Repressor Proteins
Risk Factors
ALSPAC
DNA methylation
Europeans
Meta-analysis
Prevalent T2D
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
23 02 2021
23 02 2021
Historique:
received:
01
10
2020
accepted:
11
02
2021
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is a heterogeneous disease with well-known genetic and environmental risk factors contributing to its prevalence. Epigenetic mechanisms related to changes in DNA methylation (DNAm), may also contribute to T2D risk, but larger studies are required to discover novel markers, and to confirm existing ones. We performed a large meta-analysis of individual epigenome-wide association studies (EWAS) of prevalent T2D conducted in four European studies using peripheral blood DNAm. Analysis of differentially methylated regions (DMR) was also undertaken, based on the meta-analysis results. We found three novel CpGs associated with prevalent T2D in Europeans at cg00144180 (HDAC4), cg16765088 (near SYNM) and cg24704287 (near MIR23A) and confirmed three CpGs previously identified (mapping to TXNIP, ABCG1 and CPT1A). We also identified 77 T2D associated DMRs, most of them hypomethylated in T2D cases versus controls. In adjusted regressions among diabetic-free participants in ALSPAC, we found that all six CpGs identified in the meta-EWAS were associated with white cell-types. We estimated that these six CpGs captured 11% of the variation in T2D, which was similar to the variation explained by the model including only the common risk factors of BMI, sex, age and smoking (R This study identifies novel loci associated with T2D in Europeans. We also demonstrate associations of the same loci with other traits. Future studies should investigate if our findings are generalizable in non-European populations, and potential roles of these epigenetic markers in T2D etiology or in determining long term consequences of T2D.
Sections du résumé
BACKGROUND
Type 2 diabetes (T2D) is a heterogeneous disease with well-known genetic and environmental risk factors contributing to its prevalence. Epigenetic mechanisms related to changes in DNA methylation (DNAm), may also contribute to T2D risk, but larger studies are required to discover novel markers, and to confirm existing ones.
RESULTS
We performed a large meta-analysis of individual epigenome-wide association studies (EWAS) of prevalent T2D conducted in four European studies using peripheral blood DNAm. Analysis of differentially methylated regions (DMR) was also undertaken, based on the meta-analysis results. We found three novel CpGs associated with prevalent T2D in Europeans at cg00144180 (HDAC4), cg16765088 (near SYNM) and cg24704287 (near MIR23A) and confirmed three CpGs previously identified (mapping to TXNIP, ABCG1 and CPT1A). We also identified 77 T2D associated DMRs, most of them hypomethylated in T2D cases versus controls. In adjusted regressions among diabetic-free participants in ALSPAC, we found that all six CpGs identified in the meta-EWAS were associated with white cell-types. We estimated that these six CpGs captured 11% of the variation in T2D, which was similar to the variation explained by the model including only the common risk factors of BMI, sex, age and smoking (R
CONCLUSIONS
This study identifies novel loci associated with T2D in Europeans. We also demonstrate associations of the same loci with other traits. Future studies should investigate if our findings are generalizable in non-European populations, and potential roles of these epigenetic markers in T2D etiology or in determining long term consequences of T2D.
Identifiants
pubmed: 33622391
doi: 10.1186/s13148-021-01027-3
pii: 10.1186/s13148-021-01027-3
pmc: PMC7903628
doi:
Substances chimiques
ABCG1 protein, human
0
ATP Binding Cassette Transporter, Subfamily G, Member 1
0
Carrier Proteins
0
MIRN23a microRNA, human
0
MicroRNAs
0
Repressor Proteins
0
TXNIP protein, human
0
CPT1A protein, human
EC 2.3.1.21
Carnitine O-Palmitoyltransferase
EC 2.3.1.21
HDAC4 protein, human
EC 3.5.1.98
Histone Deacetylases
EC 3.5.1.98
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
40Subventions
Organisme : Wellcome Trust
ID : 217065/Z/19/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/I025263/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700704
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT092830/Z/10/Z
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/07/008/24066
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/07/008/24066
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S036520/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 092731
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K026992/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/1/2/8
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBI025751/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S009310/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/5
Pays : United Kingdom
Références
Clin Epigenetics. 2016 Jan 28;8:13
pubmed: 26823690
Hum Mol Genet. 2015 Sep 15;24(18):5330-44
pubmed: 26101197
Nat Genet. 2017 Jan;49(1):131-138
pubmed: 27918535
Bioinformatics. 2016 Feb 15;32(4):587-9
pubmed: 26508757
Lancet. 2011 Jul 9;378(9786):169-81
pubmed: 21705072
Bioinformatics. 2016 Jan 15;32(2):286-8
pubmed: 26424855
Acta Diabetol. 2015 Oct;52(5):821-7
pubmed: 25841587
Eur J Epidemiol. 2020 May;35(5):483-517
pubmed: 32367290
Gesundheitswesen. 2005 Aug;67 Suppl 1:S19-25
pubmed: 16032513
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
PLoS One. 2016 Mar 28;11(3):e0152314
pubmed: 27019061
Cell Rep. 2018 Jun 12;23(11):3300-3311
pubmed: 29898400
BMC Bioinformatics. 2012 May 08;13:86
pubmed: 22568884
Diabetes. 2016 May;65(5):1231-44
pubmed: 26861784
Mol Metab. 2018 Aug;14:12-25
pubmed: 29496428
Diabetologia. 2016 Jan;59(1):130-138
pubmed: 26433941
Diabetes. 2017 Nov;66(11):2888-2902
pubmed: 28566273
Nat Rev Genet. 2013 Aug;14(8):585-94
pubmed: 23817309
Diabetes. 2010 Dec;59(12):3229-39
pubmed: 20858683
Front Endocrinol (Lausanne). 2018 Dec 04;9:744
pubmed: 30564199
Hum Mol Genet. 2015 Aug 1;24(15):4464-79
pubmed: 25935004
Hum Mol Genet. 2017 Aug 1;26(15):3001-3013
pubmed: 28453778
Clin Epigenetics. 2017 Oct 13;9:112
pubmed: 29046734
Endocr Rev. 2016 Jun;37(3):278-316
pubmed: 27159875
Hum Mol Genet. 2016 Feb 1;25(3):609-19
pubmed: 26643952
BMC Genomics. 2014 Oct 04;15:860
pubmed: 25282492
Nutrients. 2019 Nov 17;11(11):
pubmed: 31744183
Circ Cardiovasc Genet. 2016 Oct;9(5):436-447
pubmed: 27651444
Epigenetics Chromatin. 2013 Aug 06;6(1):26
pubmed: 23919675
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Int J Epidemiol. 2019 Feb 1;48(1):58-70
pubmed: 30107520
Int J Epidemiol. 2012 Dec;41(6):1576-84
pubmed: 22253310
Eur J Epidemiol. 2017 Sep;32(9):807-850
pubmed: 29064009
Nat Genet. 2010 Feb;42(2):105-16
pubmed: 20081858
Circulation. 2014 Aug 12;130(7):565-72
pubmed: 24920721
Genome Med. 2020 Mar 2;12(1):25
pubmed: 32114984
Nature. 2017 Jan 5;541(7635):81-86
pubmed: 28002404
Bioinformatics. 2012 Nov 15;28(22):2986-8
pubmed: 22954632
Diabetes Care. 1998 Dec;21 Suppl 3:C3-6
pubmed: 9850478
Nat Rev Genet. 2011 Jul 12;12(8):529-41
pubmed: 21747404
Diabetes. 2019 Dec;68(12):2315-2326
pubmed: 31506343
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
BMC Geriatr. 2007 Dec 05;7:28
pubmed: 18053258
Diabetes. 2014 Feb;63(2):801-7
pubmed: 24170695
Nat Genet. 2010 Feb;42(2):142-8
pubmed: 20081857
Diabetologia. 2018 Feb;61(2):354-368
pubmed: 29164275
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Bioinformatics. 2018 Dec 1;34(23):3983-3989
pubmed: 29931280
Front Pharmacol. 2018 Apr 24;9:207
pubmed: 29740313
Nat Genet. 2018 Nov;50(11):1505-1513
pubmed: 30297969
Int J Epidemiol. 2019 Jun 1;48(3):887-898
pubmed: 31257439
Nat Genet. 2014 Mar;46(3):234-44
pubmed: 24509480
Hum Mol Genet. 2014 Jan 15;23(2):534-45
pubmed: 24014485
Lancet Diabetes Endocrinol. 2015 Jul;3(7):526-534
pubmed: 26095709
Genome Biol. 2016 Mar 31;17:61
pubmed: 27036880
J Lipid Res. 2014 Jul;55(7):1324-30
pubmed: 24711635
Int J Epidemiol. 2018 Aug 1;47(4):1042-1042r
pubmed: 29546429
Nat Commun. 2019 Sep 19;10(1):4267
pubmed: 31537805
Epigenetics. 2016 Jul 2;11(7):482-8
pubmed: 27148772
Nutr Metab Cardiovasc Dis. 2017 Mar;27(3):225-233
pubmed: 28139377
Diabetes Care. 2020 Apr;43(4):875-884
pubmed: 32033992
Circ Cardiovasc Genet. 2015 Apr;8(2):334-42
pubmed: 25583993
Diabetes Care. 2012 Dec;35(12):2600-6
pubmed: 23139370
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):645-652
pubmed: 29326313
PLoS One. 2016 Jan 25;11(1):e0145789
pubmed: 26808626
Epigenetics. 2017 Jun 3;12(6):401-415
pubmed: 28059593